ALLUVI: A THOROUGH DIVE INTO THE DRUG'S POSSIBILITY

Alluvi, previously known as LY3414901, represents a exciting advancement in weight management. This combined-action glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receiver agonist demonstrates remarkable effectiveness in early trial data, with impressive sl